Business Description
Big Pharma Split Corp
NAICS : 523930
SIC : 7214
ISIN : CA08934P1080
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.57 | |||||
Debt-to-EBITDA | N/A | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -24.3 | |||||
3-Year EPS without NRI Growth Rate | -34.1 | |||||
3-Year FCF Growth Rate | 30.7 | |||||
3-Year Book Growth Rate | -1.2 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.15 | |||||
9-Day RSI | 25.97 | |||||
14-Day RSI | 30.95 | |||||
6-1 Month Momentum % | 10.86 | |||||
12-1 Month Momentum % | 2.08 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 8.87 | |||||
Dividend Payout Ratio | 1.25 | |||||
Forward Dividend Yield % | 8.87 | |||||
5-Year Yield-on-Cost % | 10.9 | |||||
3-Year Average Share Buyback Ratio | -7.6 | |||||
Shareholder Yield % | 13.8 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Net Margin % | 77.61 | |||||
FCF Margin % | 139.75 | |||||
ROE % | 10.26 | |||||
ROA % | 6.15 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 14.09 | |||||
PE Ratio without NRI | 14.09 | |||||
PS Ratio | 7.51 | |||||
PB Ratio | 1 | |||||
Price-to-Tangible-Book | 1 | |||||
Price-to-Free-Cash-Flow | 5.4 | |||||
Price-to-Operating-Cash-Flow | 5.4 | |||||
EV-to-Revenue | 6.54 | |||||
EV-to-FCF | 4.81 | |||||
Price-to-Graham-Number | 0.79 | |||||
FCF Yield % | 19.19 | |||||
Forward Rate of Return (Yacktman) % | 15.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Big Pharma Split Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 2.166 | ||
EPS (TTM) (C$) | 0.99 | ||
Beta | 0.66 | ||
Volatility % | 12.84 | ||
14-Day RSI | 30.95 | ||
14-Day ATR (C$) | 0.081802 | ||
20-Day SMA (C$) | 14.218 | ||
12-1 Month Momentum % | 2.08 | ||
52-Week Range (C$) | 13.2 - 14.97 | ||
Shares Outstanding (Mil) | 1.13 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Big Pharma Split Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Big Pharma Split Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Big Pharma Split Corp Frequently Asked Questions
What is Big Pharma Split Corp(TSX:PRM)'s stock price today?
When is next earnings date of Big Pharma Split Corp(TSX:PRM)?
Does Big Pharma Split Corp(TSX:PRM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |